




MEDICINAL PRODUCTS 2021

NUTRA PHARMA CORP
Rank 47 of 52





RealRate

MEDICINAL PRODUCTS 2021

NUTRA PHARMA CORP Rank 47 of 52



The relative strengths and weaknesses of NUTRA PHARMA CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of NUTRA PHARMA CORP compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 41% points. The greatest weakness of NUTRA PHARMA CORP is the variable Assets, Current, reducing the Economic Capital Ratio by 61% points.

The company's Economic Capital Ratio, given in the ranking table, is -174%, being 119% points below the market average of -55%.

Input Variable	Value in 1000 USD
Assets, Current	55
Assets, Non-Current	144
General and Administrative Expense	1,101
Goodwill	0
Liabilities, Current	11,483
Liabilities, Non-Current	60
Other Assets	88
Other Compr. Net Income	0
Other Expenses	-125
Other Liabilities	253
Other Net Income	156
Other Revenues	52
Property, Plant and Equipment, Net	15
Research and Development	0

Output Variable	Value in 1000 USD
Liabilities	11,796
Assets	302
Expenses	977
Revenues	52
Stockholders Equity	-11,494
Net Income	-769
Comprehensive Net Income	-769
Economic Capital Ratio	-174%